Articles Archives - Page 135 of 713

FridaySep 15, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) is On Track for IND Application with the FDA for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria’s IND application for its U.S. Phase 1b Hypertension Clinical Study, HYPER-H23-1, remains on track despite setbacks Work mostly under Lexaria’s control was completed earlier this year, while work that is outside its control remains delayed Regardless, Lexaria continues to make progress, even as it looks to take advantage of the growing global cardiovascular drugs market, which is projected to post a CAGR of 3.1% between 2021 and 2026 Chris Bunka, Lexaria’s CEO, has lauded the company’s exceptional discovery, which demonstrates the ability of the patented DehydraTECH-processed CBD to lower blood pressure in the patient population Lexaria Bioscience (NASDAQ: LEXX),…

ThursdaySep 14, 2023 9:00 am

Leadership Changes At SOHM, Inc. (SHMN) to Strengthen Growth Strategies for Generic Drug Market and Gene Editing Platform Development

U.S.-based generic drug developer SOHM recently announced the addition of two leading officers — Dr. David Aguilar (Ph.D) as Chief Operating Officer and Dr. Krishna Bhat (MD, Ph.D, FACC) as Chief Medical Advisor The new officers are expected to help direct SOHM’s global growth strategy as the company continues to develop and diversify its product offerings, which include a variety of mediums for administering antibiotics, analgesics, anti-inflammatory and anti-cold therapies, as well as vitamins SOHM also recently announced an LOI to acquire a stem cell disruptive technology and related patents, which include the potential for someday treating damaged hearts via…

WednesdaySep 13, 2023 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

PaxMedica recently announced positive top line results from its PAX-101 Phase 3 African Sleeping Sickness Study, paving the way for an expected New Drug Application filing in 2024 The company granted exclusive pharmacy distribution for PAX-101 to Vox Nova LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with ASD PaxMedica submitted PAX-101 Clinical Trial Request to the South African Health Products Regulatory Authority, requesting approval for a double-blind, placebo-controlled study in ASD The company entered a Research Collaboration Agreement with PoloMar Health and The BRAIN Foundation for a Phase II proof-of-concept trial in ASD PaxMedica (NASDAQ:…

WednesdaySep 13, 2023 9:45 am

RJD Green Inc. (RJDG) Strongly Positioned with Diversified “Recession Resistant” Portfolio

RJDG acquires and manages assets in three diverse markets: construction, digital healthcare services, and environmental solutions Asset portfolio includes Silex Interiors, ioSoft Inc., and Earthlinc Environmental Solutions Silex Interiors manufactures, distributes, and installs bathroom and kitchen furniture, countertops, and related products; awarded contract that is expected to generate $850,000+ revenue in 2023 ioSoft Inc. provides secure payment technologies, cloud-based software, and professional services to healthcare industry; recently procured software development and IT support contract to customize ioSoft Suites for the RailPro Group Earthlinc Environmental Solutions offers patented waste processing technology for commercial chicken and hog farms; transforms waste into animal…

WednesdaySep 13, 2023 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Delivers Power of Quantum to Solve Business Optimization Problems

D-Wave’s quantum solutions help businesses solve computationally complex optimization problems, including logistics, employee scheduling, factory processes, and more Advantage(TM) is D-Wave’s fifth-generation quantum computer featuring industry-leading 5,000+ qubits and 15-way qubit connectivity D-Wave’s commercial customers include blue-chip industry leaders like Mastercard, Deloitte, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., and Lockheed Martin Business leaders today are faced with a myriad of solutions to consider for integration into their organization’s IT infrastructure, many of which are critical in achieving meaningful operational efficiency and business advantage. One of the most promising yet perplexing solutions is quantum computing. Most businesses are…

TuesdaySep 12, 2023 9:45 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) NanoAbs for Psoriasis Treatment May Offer Significant Advantages Over Apogee

About 125 million people worldwide have psoriasis, a chronic disease where the immune system becomes overactive, causing skin cells to multiply too quickly The psoriasis treatment market is expected to reach $48.33 billion by 2030, driven by an increase in diagnosed patients and the prevalence of skin disorders in developed nations Scinai’s NanoAbs targeting the IL-17 family of cytokines, which have shown promise in treating psoriasis, may offer significant advantages over Apogee Therapeutics, whose recent IPO has resulted in a $1 billion market cap Scinai’s NanoAbs offer additional routes of administration, a higher affinity and binding to the target, and…

TuesdaySep 12, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Investigational Research Programs Position the Company for Important Partnership Opportunities and Growth

Lexaria Bioscience has completed several studies that confirm and support the superiority and advantages of its patented DehydraTECH(TM) technology over traditional oral delivery methods The company recently announced results from its human oral nicotine study NIC-H22-1 comparing its DehydraTECH-nicotine pouch to world-leading brands, Zyn(R) and on!(R) Results from the study demonstrated that DehydraTECH-nicotine was statistically significantly faster in reaching Tmax than both brands Lexaria has also undertaken other investigational research programs, including the analysis and execution of hypertension, diabetes, hormone therapy, and dementia studies, which could birth excellent partnership opportunities, supporting further growth A report by Zacks Investment Research discussed…

MondaySep 11, 2023 12:00 pm

Shoals Technologies Group, Inc. (NYSE: SHLS) Featured in Coverage of the ROTH MKM 10th Annual Solar & Storage Symposium

Shoals Technologies Group (NYSE: SHLS) is a leading provider of electrical balance of systems (“EBOS”) solutions for solar, storage, and electric vehicle charging infrastructure. Since its founding in 1996, the company has introduced innovative technologies and systems solutions that allow its customers to substantially increase installation efficiency and safety while improving system performance and reliability. Shoals Technologies Group, Inc. is a recognized leader in the renewable energy industry whose solutions are deployed on over 62 GW of solar systems globally. For more information, visit the company's website at www.Shoals.com. To schedule a one-on-one meeting, please contact your ROTH MKM representative. To…

MondaySep 11, 2023 11:15 am

SuperCom Ltd. (NASDAQ: SPCB) Offers its Newest Solution for Increasing Public Safety, Reducing Domestic Violence, While Cutting Government Costs

SuperCom has introduced the all-in-one PureOne monitoring device with three unique tech modules, offering advanced technology for the cost-effective electronic home and civil monitoring of offenders The electronic offender monitoring market in Europe and the Americas is expected to reach $2.1 billion in 2026 and is seeking new technologies to meet a rapidly growing demand SuperCom’s innovative solutions promise a critical technological and social impact – improving public safety worldwide and reducing governmental costs in the process The company’s growth strategy includes potential acquisitions and expansion into new regions with limited electronic monitoring capabilities SuperCom (NASDAQ: SPCB), a leading global…

MondaySep 11, 2023 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) to Attend H.C. Wainwright 25th Annual Global Investment Conference and Discuss UPNEEQ(R) for Treating Acquired Blepharoptosis

RVL Pharmaceuticals' CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year's H.C. Wainwright Annual Global Investment Conference in New York City The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis RVL Pharmaceuticals plans to continue marketing to medical aesthetics providers and will launch a direct-to-consumer campaign later this year The medical aesthetics market was valued at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027 RVL Pharmaceuticals (NASDAQ:…

Site Search

Company Search

Category: Articles